Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.

Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F

doi:10.1007/s00432-018-02833-8

PURPOSE: Hormone receptors (HR) status in HER2 + breast cancer (BC) is a recognized stratification factor with relevant clinical implication. According to HR expression, HER2 + BC show different clinical characteristics, treatment sensitivity and prognosis. The interaction between HR and HER2 pathways remains incompletely understood. METHODS: Thirty-four HER2 + BC were included: 18 tumors with HER2+/HR + and 16 with HER2+/HR-. The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer Pathway panel performed on FFPE BC biopsies. RESULTS: Gene expression analysis identified 127 genes with significantly different expression between the two cohorts. 83% of these genes were overexpressed in HER2+/HR- cohort. Globally, 23% of them belonged to PI3K pathway (41 genes), 15% to Trascriptional regulation (26 genes) and 12% to MAPK (22 genes). Regarding pathway expression, PI3K, MAPK and NOTCH were significantly differently expressed between the two groups (p = 0.003, p = 0.0018 and p = 0.02, respectively), all of them were overexpressed in HER2+/HR- tumors. CONCLUSIONS: According to HR status, HER2 + tumors express different pathways profiles: the overexpression of PI3K, MAPK and NOTCH pathways in HER2+/HR- group could justify different survival outcomes and treatment sensitivity. The identification of tumor driver pathways may be a useful instrument for individualized pathway-directed therapies. Further clinical implications are warranted.

Data di pubblicazione:	2019
Titolo:	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
Autore/i:	Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F
Autore/i UNIMORE:	OMARINI, Claudia BETTELLI, Stefania Raffaella Caprera C MANFREDINI, SAMANTHA BARBOLINI, MONICA Moscetti L ISCA, CHRYSTEL TOSS, ANGELA BARBIERI, Elena Cortesi L KALECI, SHANIKO MAIORANA, Antonino TAZZIOLI, Giovanni CASCINU, Stefano PIACENTINI, Federico mostra contributor esterni nascondi contributor esterni
Digital Object Identifier (DOI):	10.1007/s00432-018-02833-8
Rivista:	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Pagina iniziale:	1
Pagina finale:	1
Codice identificativo ISI:	WOS:000462617300003
Codice identificativo Scopus:	2-s2.0-85059460537
Codice identificativo Pubmed:	30603906
Citazione:	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status / Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - (2019), pp. 1-1.
Tipologia	Articolo su rivista

File in questo prodotto:

File	Descrizione	Tipologia
DIFFERENTIAL.pdf	Articolo principale	Versione editoriale	Administrator Richiedi una copia

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11380/1169004

Citazioni

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris